Recently, pemigatinib, an FGFR2 inhibitor used in patients with FGFR2-rearranged cholangiocarcinoma, received FDA approval for relapsed/refractory myeloid and/or lymphoid neoplasms with FGFR1 rearrangements. This evidence concerns the gene FGFR2 and lymphoid neoplasm.